Status:
UNKNOWN
The Success of Opening Concurrent CTO leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease
Lead Sponsor:
Beijing Anzhen Hospital
Collaborating Sponsors:
The First Affiliated Hospital of Dalian Medical University
Beijing Friendship Hospital
Conditions:
Chronic Total Occlusion of Coronary Artery
Percutaneous Coronary Intervention
Eligibility:
All Genders
18-80 years
Brief Summary
The purpose of this study is to investigate the effect of percutaneous coronary intervention (PCI) on cardiac function in multi-vessel disease patients with concurrent chronic total occlusion (CTO) le...
Detailed Description
Recruited CTO patients will be devided into two groups: those undergoing PCI of only the non-CTO artery (non-CTO PCI group), and those undergoing PCI of the non-CTO artery concurrently with the CTO ar...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients should be 18-80 years old; be diagnosed with single CTO concurrent with MVD detected using coronary angiography (at least one other major vessel should have exhibited no less than 75% stenosis); present with an LVEF above 35% determined using transthoracic echocardiography; present with CTO located in an epicardial coronary artery with a reference diameter of ≥ 2.5 mm; and comply all the evaluations and follow-up protocols.
- Exclusion criteria:
- Patients will be excluded if they have suffered from acute myocardial infarction within the previous 3 months; a lesion located in the left main artery (stenosis ≥50%); rheumatic valvular disease; severe arrhythmia; a history of revascularization within the non-CTO artery; multiple vessels with CTO (more than one CTO artery); lesions unsuitable for PCI; severely abnormal hematopoietic systems, such as platelet counts \<100 x 109/L or \> 700 x 109/L and white blood cell counts \< 3 x 109/L; with active bleeding or bleeding tendencies (active ulcers, short-term ischemic stroke, history of hemorrhagic stroke, intracranial space occupying lesions, recent craniocerebral trauma, and other bleeding or bleeding tendency); severe coexisting conditions, including severe renal function dysfunction \[Glomerular filtration rate (GFR) less than 60 ml/min • 1.73 m2), severe hepatic dysfunction \[glutamic-pyruvic transaminase (ALT) or glutamic-oxal acetic transaminase (ALT) elevated more than three times that of the upper limit of the normal reference\], severe heart failure (NYHA classification III-IV), acute infectious diseases and immune disorders; tumors; surgery within 3 months; a life expectancy less than 12 months; pregnancy or planning to become pregnant; history of allergy or adverse reactions to aspirin, clopidogrel, ticagrelor, stains, contrast material, anticoagulant, or stents. Patients will also be excluded if they cannot tolerate dual antiplatelet treatment (DAPT); are unable to communicate due to cognitive impairment, auditory, or visual impairment; are participating in another trial for medication or an apparatus and in which the main endpoint has not been reached, or plan to participate in a clinical trial within 12 months of the intervention.
Exclusion
Key Trial Info
Start Date :
April 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2022
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT03372785
Start Date
April 10 2018
End Date
April 1 2022
Last Update
September 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University
Beijing, China